The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused stomach paralysis, vision loss, and other severe complications not clearly ...

Hyderabad-based Natco Pharma has filed a lawsuit against Danish drugmaker Novo Nordisk, the maker of blockbuster weight-loss ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Indianapolis: Eli Lilly and Company has announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

U.S. District Judge Karen Marston, of the Eastern District of Pennsylvania, allowed some misrepresentation claims to go ...

Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...